The effect of Suffentanil- dexmedetomidine in Spinal Anesthesia of Patients Undergoing lower abdominal and lower extremity surgery

The comparison of the effect of Suffentanil- dexmedetomidine in Spinal Anesthesia of Patients Undergoing lower abdominal and lower extremity surgery; a clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017082833680N3

Enrollment

Registered

2017-09-25

Start date

2017-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower abdominal and lower extremity surgery under spinal anesthesia. Dissociative anaesthesia and sensory loss

Interventions

Intervention 1: The control group received 15 mg bupivacaine plus 3 µg of sufentanil. Intervention 2: The intervention group received 15 mg bupivacaine plus 3 µg of sufentanil and 10 µg doxedemodoimid

Placebo

Treatment - Drugs

The control group received 15 mg bupivacaine plus 3 µg of sufentanil

The intervention group received 15 mg bupivacaine plus 3 µg of sufentanil and 10 µg doxedemodoimidine to spinal anesthesia

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who are in the age range of 18-60 year; patient's consent of spinal anesthesia. Exclusion criteria: Addiction; history of diabetics; history of neuropathy; history of neuromascular disease; drug allergy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Duration of sensory and motor blockade. Timepoint: After surgery. Method of measurement: Time.;Return of hemodynamic changes blocked. Timepoint: After surgery. Method of measurement: Questionnare.;Housing consumption. Timepoint: After surgery. Method of measurement: Dosage.	—

Secondary

Measure	Time frame
Age. Timepoint: Before intervention. Method of measurement: Years.;Sex. Timepoint: Before intervention. Method of measurement: Male of female.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mojtaba Karimi

Mashhad University of Medical Sciences

Kaimim931@mums.ac.ir+98 518022711

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 15, 2026